Dr David Chan, a medical oncologist, has been a Sydney Vital member for over three years. David is especially interested in the area of NETs, uncommon tumours marked by significant heterogeneity in clinical course and prognosis. Previously considered to be rare, NETs are increasing in incidence (5/100,000) and have a relatively high prevalence as people may survive with it for a long time (second most prevalent gastrointestinal cancer after colon cancer.)
His paper ‘Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance‘ describes a scoring scale (NETPET) for this uncommon tumour group, which has been published in Thernanostics. It shows that NETPET score correlated with histological grade and survival and is the first study to evidence that dual PET can be used to predict outcomes and is now used internationally.
Dr Chan was supported by Sydney Vital for his fellowship in 2016 which directly resulted in the development of this research. Dr Chan’s fellowship work and expanded by Dr Hayes has received recognition through a major publication and in 2016 was presented at the Society of Nuclear Medicine (Continuing Education Session) and as a “Green Lecture” to Canadian NETs Groups. Dr Chan is continuing his research at the Bill Walsh laboratory in the Kolling Institute and has a planned PhD arising from this topic.
Here more about ‘Dual PET scans for neuroendocrine tumours‘ in the latest episode of Vital Cast.